|
1.
|
Grignani F, De Matteis S, Nervi C,
Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara
FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci
PG: Fusion proteins of the retinoic acid receptor-alpha recruit
histone deacetylase in promyelocytic leukaemia. Nature.
391:815–818. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH
Jr and Evans RM: Role of the histone deacetylase complex in acute
promyelocytic leukaemia. Nature. 391:811–814. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ
and Chen Z: Treatment of acute promyelocytic leukemia with ATRA and
As2O3: a model of molecular target-based cancer therapy. Cancer
Biol Ther. 1:614–620. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Zhang JW, Wang JY, Chen SJ and Chen Z:
Mechanisms of all-trans retinoic acid-induced differentiation of
acute promyelocytic leukemia cells. J Biosci. 25:275–284. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Melnick A and Licht JD: Deconstructing a
disease: RARalpha, its fusion partners, and their roles in the
pathogenesis of acute promyelocytic leukemia. Blood. 93:3167–3215.
1999.PubMed/NCBI
|
|
7.
|
Tallman MS and Altman JK: Curative
strategies in acute promyelocytic leukemia. Hematology Am Soc
Hematol Educ Program. 1:391–399. 2008. View Article : Google Scholar
|
|
8.
|
Thirugnanam R, George B, Chendamarai E,
Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy
M and Mathews V: Comparison of clinical outcomes of patients with
relapsed acute promyelocytic leukemia induced with arsenic trioxide
and consolidated with either an autologous stem cell transplant or
an arsenic trioxide-based regimen. Biol Blood Marrow Transplant.
15:1479–1484. 2009. View Article : Google Scholar
|
|
9.
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG
and Heinzel T: Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001.PubMed/NCBI
|
|
10.
|
Quintás-Cardama A, Santos FP and
Garcia-Manero G: Histone deacetylase inhibitors for the treatment
of myelodysplastic syndrome and acute myeloid leukemia. Leukemia.
25:226–235. 2011.PubMed/NCBI
|
|
11.
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cheng YC, Lin H, Huang MJ, Chow JM, Lin S
and Liu HE: Downregulation of c-Myc is critical for valproic
acid-induced growth arrest and myeloid differentiation of acute
myeloid leukemia. Leuk Res. 31:1403–1411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Cimino G, Lo-Coco F, Fenu S, Travaglini L,
Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F,
Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F,
Pelicci PG and Nervi C: Sequential valproic acid/all-trans retinoic
acid treatment reprograms differentiation in refractory and
high-risk acute myeloid leukemia. Cancer Res. 66:8903–8911. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kuendgen A, Schmid M, Schlenk R, Knipp S,
Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H and Gattermann
N: The histone deacetylase (HDAC) inhibitor valproic acid as
monotherapy or in combination with all-trans retinoic acid in
patients with acute myeloid leukemia. Cancer. 106:112–119. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kuendgen A, Strupp C, Aivado M, Bernhardt
A, Hildebrandt B, Haas R, Germing U and Gattermann N: Treatment of
myelodysplastic syndromes with valproic acid alone or in
combination with all-trans retinoic acid. Blood. 104:1266–1269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Duprez E, Wagner K, Koch H and Tenen DG:
C/EBPbeta: a major PML-RARA-responsive gene in retinoic
acid-induced differentiation of APL cells. EMBO J. 22:5806–5816.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Guibal FC, Alberich-Jorda M, Hirai H,
Ebralidze A, Levantini E, Di Ruscio A, Zhang P, Santana-Lemos BA,
Neuberg D, Wagers AJ, Rego EM and Tenen DG: Identification of a
myeloid committed progenitor as the cancer-initiating cell in acute
promyelocytic leukemia. Blood. 114:5415–5425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Mueller BU, Pabst T, Fos J, Petkovic V,
Fey MF, Asou N, Buergi U and Tenen DG: ATRA resolves the
differentiation block in t(15;17) acute myeloid leukemia by
restoring PU.1 expression. Blood. 107:3330–3338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Park DJ, Chumakov AM, Vuong PT, Chih DY,
Gombart AF, Miller WH Jr and Koeffler HP: CCAAT/enhancer binding
protein epsilon is a potential retinoid target gene in acute
promyelocytic leukemia treatment. J Clin Invest. 103:1399–1408.
1999. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Rosmarin AG, Yang Z and Resendes KK:
Transcriptional regulation in myelopoiesis: Hematopoietic fate
choice, myeloid differentiation, and leukemogenesis. Exp Hematol.
33:131–143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zhang K, Li J, Meng W, Xing H and Yang Y:
C/EBPbeta and CHOP participate in tanshinone IIA-induced
differentiation and apoptosis of acute promyelocytic leukemia cells
in vitro. Int J Hematol. 92:571–578. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tenen DG: Disruption of differentiation in
human cancer: AML shows the way. Nat Rev Cancer. 3:89–101. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Yoshino Y, Yuan B, Kaise T, Takeichi M,
Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of
aquaporin 9 and multidrug resistance-associated protein 2 to
differential sensitivity to arsenite between primary cultured
chorion and amnion cells prepared from human fetal membranes.
Toxicol Appl Pharmacol. 257:198–208. 2011. View Article : Google Scholar
|
|
24.
|
Iriyama N, Yuan B, Hatta Y, Horikoshi A,
Yoshino Y, Toyoda H, Aizawa S and Takeuchi J: Granulocyte
colony-stimulating factor potentiates differentiation induction by
all-trans retinoic acid and arsenic trioxide and enhances arsenic
uptake in the acute promyelocytic leukemia cell line HT93A. Oncol
Rep. 28:1875–1882. 2012.
|
|
25.
|
Yuan B, Ohyama K, Takeichi M and Toyoda H:
Direct contribution of inducible nitric oxide synthase expression
to apoptosis induction in primary smooth chorion trophoblast cells
of human fetal membrane tissues. Int J Biochem Cell Biol.
41:1062–1069. 2009. View Article : Google Scholar
|
|
26.
|
Kosugi H, Towatari M, Hatano S, Kitamura
K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H
and Naoe T: Histone deacetylase inhibitors are the potent
inducer/enhancer of differentiation in acute myeloid leukemia: a
new approach to anti-leukemia therapy. Leukemia. 13:1316–1324.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Morosetti R, Park DJ, Chumakov AM,
Grillier I, Shiohara M, Gombart AF, Nakamaki T, Weinberg K and
Koeffler HP: A novel, myeloid transcription factor, C/EBP epsilon,
is upregulated during granulocytic, but not monocytic,
differentiation. Blood. 90:2591–2600. 1997.PubMed/NCBI
|
|
28.
|
Inazawa Y, Saeki K and Yuo A: Granulocyte
colony-stimulating factor-induced terminal maturation of human
myeloid cells is specifically associated with up-regulation of
receptor-mediated function and CD10 expression. Int J Hematol.
77:142–151. 2003. View Article : Google Scholar
|
|
29.
|
Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li
X, Cheng F, Waxman S, Chen GQ, Chen SJ, Lanotte M, Chen Z and Tong
JH: Rapid induction of cAMP/PKA pathway during retinoic
acid-induced acute promyelocytic leukemia cell differentiation.
Leukemia. 18:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Zhang K, Guo QL, You QD, Yang Y, Zhang HW,
Yang L, Gu HY, Qi Q, Tan Z and Wang X: Wogonin induces the
granulocytic differentiation of human NB4 promyelocytic leukemia
cells and up-regulates phospholipid scramblase 1 gene expression.
Cancer Sci. 99:689–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kawagoe R, Kawagoe H and Sano K: Valproic
acid induces apoptosis in human leukemia cells by stimulating both
caspase-dependent and -independent apoptotic signaling pathways.
Leuk Res. 26:495–502. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Leiva M, Moretti S, Soilihi H, Pallavicini
I, Peres L, Mercurio C, Dal Zuffo R, Minucci S and de Thé H:
Valproic acid induces differentiation and transient tumor
regression, but spares leukemia-initiating activity in mouse models
of APL. Leukemia. 26:1630–1637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Deubzer H, Busche B, Rönndahl G, Eikel D,
Michaelis M, Cinatl J, Schulze S, Nau H and Witt O: Novel valproic
acid derivatives with potent differentiation-inducing activity in
myeloid leukemia cells. Leuk Res. 30:1167–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Zapotocky M, Mejstrikova E, Smetana K,
Stary J, Trka J and Starkova J: Valproic acid triggers
differentiation and apoptosis in AML1/ETO-positive leukemic cells
specifically. Cancer Lett. 319:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ito K, Bernardi R, Morotti A, Matsuoka S,
Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J and
Pandolfi PP: PML targeting eradicates quiescent
leukaemia-initiating cells. Nature. 453:1072–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Yuan B, Yoshino Y, Kaise T and Toyoda H:
Application of arsenic trioxide therapy for patients with leukemia.
Biological Chemistry of Arsenic, Antimony and Bismuth. Sun H: John
Wiley & Sons, Ltd; Chichester: pp. 263–292. 2011
|
